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ventricular systolic heart failure and its relationship with serum pro-BNP.
Methods: Fifty-ﬁve patients with a diagnosis of systolic heart failure and 25 patients
without systolic heart failure were enrolled in this study. The study took place in the
department of cardiology at Uludag University School of Medicine between October
2011 and April 2012. Echocardiography was performed in all cases. Serum C-reactive
protein, pro-BNP and LOX-1 levels were studied.
Results: Serum LOX-1 and pro-BNP levels were signiﬁcantly higher in the heart
failure group and showed negative correlations with left ventricular ejection fraction.
However, there was no signiﬁcant correlation between serum LOX-1 and pro-BNP
levels. In addition, LOX-1 level in patients with ischemic cardiomyopathy was
signiﬁcantly higher than the patients with dilated cardiomyopathy. ROC analysis was
done for the studied sample of serum LOX-1, the ‘cut off’ level was determined as
1.31 ng/ml for LOX-1 giving a sensitivity of 56.3% and speciﬁcity of 96% for the
diagnosis of the systolic heart failure.
Conclusion: Our study demonstrates the utility of the serum LOX-1 levels in the
diagnosis of left ventricular systolic heart failure. LOX-1 may have an important place
in the diagnosis of heart failure, especially when the etiology is ischemic cardiomy-
opathy. Further prospective studies with larger sample sizes are needed to better
understand the exact role of LOX-1 in the diagnosis and assessment of heart failure.Table 1. The demographic and baseline clinical characteristics of the heart
failure and control groups
Heart failure group Control group p value
Age (years) 64 (22-83) 62 (50-78) 0.306
Hypertension (n, %) 30 (54.5%) 14 (56%) 1.000
Hyperlipidemia (n, %) 21 (38.2%) 14 (56%) 0.323
Smoking (n, %) 9 (16.4%) 2 (8%) 0.511
Left ventricular ejection fraction 27 (18-44) 65 (54-73) <0.001
Table 2. Laboratory data of the heart failure and control groups
Heart failure Control group value
Blood glucose (mg/dl) 91.417.2 90.912 0.882
Urea (mg/dl) 45 (21-99) 32 (19-44) <0.001
Creatinine (mg/dl) 0.9 (0.6-1.4) 0.7 (0.6-1.1) <0.001
GFR (ml/min/1.73 m2) 84 (44-148) 96 (65-144) 0.012
Sodium (mg/dl) 137 (125-144) 141(138-144) <0.001
Potassium (mg/dl) 4.30.51 4.4 0.44 0.602
Calcium (mg/dl) 9.0 (6.3-10.5) 9.5 (8.6-11.2) 0.001
Hemoglobin (g/dl) 12.71.97 14.3 0.86 <0.001
LOX-1 (ng/ml) 1.46 (0.56-4.09) 0.99 (0.58-1.7) <0.001
Pro-BNP (mg/ml) 3560 (211-20806) 97 (18-184) <0.001
CRP (mg/L) 0.8 (0.3-5.5) 0.33 (0-0.5) <0.001
GFR: Glomerular ﬁltration rate, CRP: C-reactive protein, LOX-1: Lectin like oxidized LDL
receptor-1, BNP: Brain natriuretic peptide
Table 3. Comparison of patients according to the etiology of heart failure
DCMP (n¼24) ICMP (n¼ 31) p value
Ejection fraction (%) 25 (18-44) 30 (19-44) 0.165
LOX-1 (ng/ml) 1.16 (0.56-2.84) 1.65 (0.64-4.09) 0.027
Pro-BNP (mg/ml) 2806 (211-17277) 5200 (248-20806) 0.044
CRP (mg/L) 0.52 (0.3-3.5) 1.3 (0.3-5.54) 0.058
CRP: C-reactive protein, LOX-1: Lectin like oxidized LDL receptor-1, BNP: Brain natriuretic
peptide, DCMP: dilated cardiomyopathy, ICMP: ischemic cardiomyopathy
Table 1
Age (years) 63.2  12.7
Male gender 168
EF (%) 26.5  6.4
Hypertension (%) 62.3
Diabetes mellitus (%) 28.9
Smoking (%) 17.3
Ischemic cardiomyopathy (%) 82.7
WBC (X1,000/ml) 12.6  4.9
Neutrophil (%) 79.3  13.5
Lymphocyte (%) 17.1  7.2
Neutrophil-to-lymphocyte ratio 6.5  4.7
Baseline characteristics and hematological variables
Table 2
Variables Group 1 Group 2 p
D WBC 0.5  2.2 1.1  5.1 0.216
D Neutrophil 3.3  7.8 - 1.1  7.7 0.001
D Lymphocyte -1.4  6.1 1.1  5.4 0.012
D NLR 1.1  3.7 -2.7  11.6 <0.001
Comparison of changes in hematological variables of the patients who survived (group 1) and
died (group 2)after levosimendan therapyOP-167
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Aim: The aim of the study was to investigate the effect of levosimendan infusion on
hematological variables in patients with acute heart failure. Also, predictive value of
these variables over in hospital mortality evaluated.C74 JACC VMethods: Two hundred and nineteen patients (168 male, 51 female, mean age
63.212.7 years) with acute exerbation of advanced heart failure (ejection fraction
35%) were included in this study. Levosimendan was initiated as a bolus of 6 mg/kg
followed by a continuous infusion of 0,1 mg/kg/min for 24 hours. Changes of
hematological variables between admission and on third day after levosimendan
infusion were evaluated. Categorical variables were expressed as frequencies and
percentages. Continuous variables were compared using analysis of variance and
Kruskal-Wallis tests for those with normal and skewed distributions, respectively.
Chi-square tests were used to compare categorical variables. Univariate and multi-
variate Cox regression models were used to evaluate the independent association of
different hematological variables with in-hospital mortality.
Results: Table 1 demonstrated the baseline demographical and laboratory
characteristics of the patients. After levosimendan therapy, signiﬁcant decrease in
WBC and neutrophil counts and increase in lymphocyte count. As a result,
neutrophil to lymphocyte ratio (NLR) decreased. Compared to patients that
survived, in patients who died during in-hospital stay, these hematological changes
not occurred (Table 2). D NLR detected as independent predictor of in hospital
mortality when other hematological variables associated with mortality analysed in
the multivariate logistic regression analysis (R2¼0.094, p¼0.003).
Conclusion: Our study showed that levosimendan treatment is associated with
signiﬁcant changes in hematological variables in patients with acute exacerbation of
advanced heart failure. The difference between baseline and post-treatment NLR is
independent predictor of in hospital mortality.OP-168
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Introduction: Disease management programs for the treatment of patients with heart
failure (HF) have been advocated by society guidelines in order to improve patient
compliance and decrease hospitalizations. However, there are several different HF
management programs; most of them are costly and are not feasible to use in various
geographic areas. The aim of this study was to assess the efﬁcacy and feasibility of
a cardiologist lead enhanced HF education at the time of hospital discharge with a 6
month phone follow- up program in chronic HF patients.
Methods: The Hit Point trial was a multicenter; randomized, controlled trial of
enhanced HF education with a 6 month phone follow-up program (EHFP) vs routine
care (RC) in patients who carried the diagnosis of HF secondary to systolic
dysfunction, had been hospitalized for HF within six months of randomization, and
had symptoms despite optimal medical therapy. Education included information on
the adherence to treatment, symptoms recognition, diet and ﬂuid intake, weight
monitoring, activity, exercise training and when to contact cardiologist. Patients wereol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
Demographic and clinical characteristics of patients
Gender
Age
(years) Qp/Qs
VSD size
(mm)
Aneurysm
inlet size
(mm) Device
Patient 1 Male 26 2.2 4 5 PmVSD
occluder
Patient 2 Female 18 2 8 18 Muscular
VSD
occluder
Patient 3 Male 36 1.6 5 19 Muscular
VSD
occluder
Patient 4 Male 36 1.6 4 19 ADO-II
Patient 5 Male 42 1.7 8 15 Muscular
VSD
occluder
Patient 6 Male 62 2 8 9 PmVSD
occluder
Patient 7 Male 21 1.7 9 13 ADO-I
Patient 8 Female 49 1.6 3 8 PmVSD
occluder
Patient 9 Female 49 1.7 3 5 Muscular
VSD
occluder
Patient
10
Male 23 2.1 5 11 ADO-II
Patient
11
Female 36 1.7 8 15 Muscular
VSD
occluder
VSD: ventricular septal defect ADO: Amplatzer Duct Occluder
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vascular death.
Results: A total of 248 patients from 10 centers in various geographical areas were
randomized: 125 to EHFP and 123 to RC at the time of hospital discharge. The mean age
of all patients was 60.813.8 years. The patients were predominantly men (73%) with
NYHAclass II - IV heart failure symptomswho had amean ejection fraction of 26.8 7.3
%. Demographic characteristics, including age, sex, laboratory evaluations and assess-
ments of cardiac function, and functional capacity were equivalent in both treatment
groups. Use of pharmacologic therapy at baseline in the patients demonstrated compli-
ance with guidelines recommended therapy. Six-month cardiovascular mortality was
signiﬁcantly higher in the RC group (p<0.05). At baseline 60% of patients in EHFP and
61% RC were in NYHA Class III and IV; at 6-month follow up only 12% in EHFP and
32% in RC were in NYHA Class III and IV. The mean number of hospitalization was
0.580.91 in EHFP and 0.641.05 in RC (p¼NS) and the mean number of emergency
roomvisitswere 0.841.15 and1.211.47, respectively at 6-month follow-up (p<0.05).
Conclusion: Our study results showed that an enhanced education lead by a cardiol-
ogist and a phone follow up program signiﬁcantly reduced the cardiovascular deaths
and number of emergency room visit within 6 months after discharge in HF patients.
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Introduction: The middle-term results of VSD closure using different devices in our
clinic are presented.
Patients and Methods: Patients undergoing transcatheter VSD closure in our clinic
between April 2007 and June 2013 were reviewed. Defects were closed in cases with
a large VSD on echocardiography, left chamber hypertrophy and hemodynamically
a Qp/Qs>1.5 and/or reversible pulmonary hypertension. In perimembranous VSD the
left disk of the occluder was placed on the left of the septum in the absence of
aneurysm. If an aneurysm was present, the left disk was placed inside it, to reduce the
risk of AV block.
Results:Median age of the patients was 8 (range, 10 months - 55 years); their average
follow-up was 3720 months and average Qp/Qs 2.00.63. Average VSD diameter
was 913 mm (3-20). Implantation was successful in 74 (92.5%) of the 80 patients.
Of these, 51 had perimembranous and 23 muscular defects. For cases with peri-
membranous defects, an eccentric Amplatzer perimembranous VSD device was
placed in 18, a Cardioﬁx muscular VSD device in 17, an Amplatzer or Cardioﬁx duct
occluder in 9, an Amplatzer muscular VSD device in 3, a Lifetech muscular VSD
device in another 3 and an ADOII device in one patient. The device was placed within
the aneurysm tissue in 18 cases. As for muscular VSD, Cardioﬁx muscular VSD
device was used in 18 patients, an Amplatzer muscular VSD device in 2, a Lifetech
muscular VSD in another 2 and a Cardioﬁx ASD occluder in one patient. Complete
occlusion immediately post-intervention was achieved in 52% (39/74), 70% (52/74)
on the next day and 85% (63/74) at the 6-month follow-up. The residual defect ratio
was signiﬁcantly higher where the device had been placed inside the aneurysm
(p<0.05). One patient had a reversible complete AV block and another one experi-
enced hemolysis, no other major complications were observed. One patient underwent
open surgery for a signiﬁcant residual defect. During follow-up, two patient had de
novo presentation of non-progressive, minimal aortic insufﬁciency.
Conclusion: VSD occlusion by different devices is safe and efﬁcacious in selected
patients. While placement of the device inside the aneurysm increases the proportion
of residual shunt, it is believed that it may reduce the risk of AV block, the most feared
complication.
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Introduction: Ventricular septal defects (VSD) are the most common congenital
heart disease. Of these defects 80% involves the membranous septum. With theJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAintroduction of eccentric perimembranous VSD (PmVSD) occluder devices, percu-
taneous closure of PmVSDs has become an accepted alternative to surgical closure.
However, closure of PmVSDs associated with septal aneurysms is more challenging.
We report our experience of device closure of PmVSD associated with septal
aneurysm.
Material-Methods: Between 2008 and 2012, percutaneous closure of PmVSD
associated with a septal aneurysm was attempted in 11 patients in our institution. The
indication for VSD closure was the presence of hemodynamically signiﬁcant PmVSD
demonstrated by cardiac catheterisation (Qp/Qs > 1.5). We used 2 methods to occlude
PmVSD associated with septal aneurysm: 1) to close the defect at the left ventricular
opening of the aneurysm by anchoring the left disc of the occluder at the the inlet
portion of the aneurysm and compressing the aneurysm and the defect between the left
and the right discs of the device; 2) to close the defect at the outlet by anchoring the
left disc of the device at the left side of the outlet portion of the aneurysm. We
preferred to use the ﬁrst method when the aneursym was small and there is adequate
distance from the aortic valve. The patients were followed up at 1st, 3rd, 6th and 12th
months after the closure procedure by TTE and ECG.
Results: Mean age of the patients was 36.21.3 and 64% were male. The demo-
graphic and clinical characteristics of patients are shown in table 1. The average
diameter of the VSD was 5.92.4 mm by angiography. One patient had 2 defects
within the aneurysm and 1 patient had dextrocardia. Large aneurysm (the inlet portion
of the aneurysm > 10 mm) was present in 7 patients. The procedure was successful in
all patients. We used Amplatzer PmVSD occluder device in 3 patients, Amplatzer
Muscular VSD occluder device in 5 patients, Amplatzer Duct occluder-I (ADO-I) in 1
patient and ADO-II device in 2 patients. We prefered to occlude the defect by the
ﬁrst method in 4 patients who had a small aneurysm and PmVSD occluder was used in
3 cases and a muscular VSD occluder device was implanted in 1 patient. Second
method was prefered in 7 patients who had larger aneurysms. A trivial residual shunt
was detected by ventriculography in 4 patients immediately after the procedure.
Complete closure was observed by transthoracic echocardiography in all patients at
the time of discharge. The patients were followed-up at mean of 221.9 months.
There was no device or procedure related complications at the acute setting or mid-
term follow-up.
Conclusion: Percutaneous closure of PmVSDs associated with aneurysm is more
challenging than simple defects. The selection of the device type and size should be
made according to the conﬁguration and size of the aneurysm and the defect.LS C75
